Trial Profile

A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Agalsidase beta (Primary) ; Cetirizine; Dexamethasone; Diphenhydramine; Fexofenadine; Loratadine; Montelukast; Paracetamol
Indications Fabry's disease
Focus Therapeutic Use
Acronyms SHORTEN
Sponsors Sanofi

Most Recent Events

26 Feb 2025 Status changed from recruiting to completed.
29 Nov 2023 Planned End Date changed from 4 Sep 2025 to 6 Oct 2025.
29 Nov 2023 Planned primary completion date changed from 4 Sep 2025 to 6 Oct 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com